Fibrogen Stock Today

FGEN Stock  USD 2.35  0.23  8.91%   

Performance

13 of 100

 
Low
 
High
Good

Odds Of Distress

Over 68

 
100  
 
Zero
Quite High
FibroGen is selling at 2.35 as of the 29th of March 2024; that is -8.91 percent decrease since the beginning of the trading day. The stock's open price was 2.58. FibroGen has more than 68 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for FibroGen are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of February 2024 and ending today, the 29th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
14th of November 2014
Category
Healthcare
Classification
Health Care
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Fibrogen Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 98.77 M outstanding shares of which 5.53 M shares are currently shorted by private and institutional investors with about 3.12 trading days to cover. More on FibroGen

Moving together with FibroGen Stock

  0.7EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against FibroGen Stock

  0.76MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.75MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.74VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.66MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr
  0.64KA Kineta Inc Financial Report 9th of May 2024 PairCorr
  0.63ME 23Andme HoldingPairCorr
  0.51MBIO Mustang Bio Report 3rd of April 2024 PairCorr

FibroGen Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. FibroGen's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding FibroGen or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO DirectorThane Wettig
Thematic IdeaCancer Fighters (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering FibroGen report their recommendations after researching FibroGen's financial statements, talking to executives and customers, or listening in on FibroGen's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering FibroGen. The FibroGen consensus assessment is calculated by taking the average forecast from all of the analysts covering FibroGen.
Financial Strength
Based on the analysis of FibroGen's profitability, liquidity, and operating efficiency, FibroGen is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. Financial strength of FibroGen is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.320.3489
Significantly Down
Very volatile
Gross Profit Margin1.010.8724
Fairly Up
Slightly volatile
Total Current Liabilities128.8 M217.7 M
Way Down
Slightly volatile
Non Current Liabilities Total261.8 M368.1 M
Way Down
Slightly volatile
Total Assets665.2 M423.5 M
Way Up
Slightly volatile
Total Current Assets463.5 M331.6 M
Significantly Up
Slightly volatile
FibroGen's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to FibroGen's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand FibroGen's financial leverage. It provides some insight into what part of FibroGen's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on FibroGen's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how FibroGen deploys its capital and how much of that capital is borrowed.
Liquidity
FibroGen cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 170.46 M in liabilities with Debt to Equity (D/E) ratio of 0.89, which is about average as compared to similar companies. FibroGen has a current ratio of 2.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist FibroGen until it has trouble settling it off, either with new capital or with free cash flow. So, FibroGen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like FibroGen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for FibroGen to invest in growth at high rates of return. When we think about FibroGen's use of debt, we should always consider it together with cash and equity.

Total Cashflows From Investing Activities

107.61 Million
FibroGen (FGEN) is traded on NASDAQ Exchange in USA. It is located in 409 Illinois Street, San Francisco, CA, United States, 94158 and employs 486 people. FibroGen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 236.06 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate FibroGen's market, we take the total number of its shares issued and multiply it by FibroGen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. FibroGen conducts business under Biotechnology sector and is part of Health Care industry. The entity has 98.77 M outstanding shares of which 5.53 M shares are currently shorted by private and institutional investors with about 3.12 trading days to cover. FibroGen currently holds about 438.13 M in cash with (315.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check FibroGen Probability Of Bankruptcy
Ownership Allocation
FibroGen retains a total of 98.77 Million outstanding shares. The majority of FibroGen outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in FibroGen to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in FibroGen. Please pay attention to any change in the institutional holdings of FibroGen as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check FibroGen Ownership Details

FibroGen Stock Price Odds Analysis

Contingent on a normal probability distribution, the odds of FibroGen jumping above the current price in 90 days from now is about 14.42%. The FibroGen probability density function shows the probability of FibroGen stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 5.2944. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, FibroGen will likely underperform. Moreover, fibroGen has an alpha of 1.7686, implying that it can generate a 1.77 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 2.35HorizonTargetOdds Above 2.35
85.53%90 days
 2.35 
14.42%
Based on a normal probability distribution, the odds of FibroGen to move above the current price in 90 days from now is about 14.42 (This FibroGen probability density function shows the probability of FibroGen Stock to fall within a particular range of prices over 90 days) .

FibroGen Stock Institutional Holders

Institutional Holdings refers to the ownership stake in FibroGen that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of FibroGen's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing FibroGen's value.
InstituionRecorded OnShares
Acadian Asset Management Llc2023-09-30
1.6 M
Morgan Stanley - Brokerage Accounts2023-09-30
1.4 M
Citadel Advisors Llc2023-09-30
1.3 M
Aqr Capital Management Llc2023-12-31
1.2 M
Jane Street Group, Llc2023-09-30
886.5 K
Northern Trust Corp2023-09-30
740.2 K
D. E. Shaw & Co Lp2023-09-30
724.4 K
683 Capital Management Llc2023-12-31
700.3 K
Renaissance Technologies Corp2023-12-31
683.4 K
Primecap Management Company2023-12-31
14.5 M
Armistice Capital, Llc2023-12-31
9.8 M
View FibroGen Diagnostics

FibroGen Historical Income Statement

FibroGen Income Statement is one of the three primary financial statements used for reporting FibroGen's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of FibroGen revenue and expense. FibroGen Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, FibroGen's Interest Expense is very stable compared to the past year. As of the 29th of March 2024, Total Revenue is likely to grow to about 179.8 M, while Depreciation And Amortization is likely to drop about 9.5 M. View More Fundamentals

FibroGen Stock Against Markets

Picking the right benchmark for FibroGen stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in FibroGen stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for FibroGen is critical whether you are bullish or bearish towards FibroGen at a given time. Please also check how FibroGen's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in FibroGen without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Volatility Now

   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Module

FibroGen Corporate Directors

FibroGen corporate directors refer to members of a FibroGen board of directors. The board of directors generally takes responsibility for the FibroGen's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of FibroGen's board members must vote for the resolution. The FibroGen board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Thomas KearnsIndependent DirectorProfile
Jorma RouttiIndependent DirectorProfile
Jeffrey EdwardsDirectorProfile
James SchoeneckIndependent DirectorProfile

How to buy FibroGen Stock?

Before investing in FibroGen, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in FibroGen. To buy FibroGen stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of FibroGen. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase FibroGen stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located FibroGen stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased FibroGen stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as FibroGen, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy FibroGen Stock please use our How to Invest in FibroGen guide.

Already Invested in FibroGen?

The danger of trading FibroGen is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of FibroGen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than FibroGen. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile FibroGen is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether FibroGen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of FibroGen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fibrogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fibrogen Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.
Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Complementary Tools for FibroGen Stock analysis

When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Bonds Directory
Find actively traded corporate debentures issued by US companies
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.536
Earnings Share
(2.92)
Revenue Per Share
1.518
Quarterly Revenue Growth
(0.21)
Return On Assets
(0.36)
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.